{"id":"https://openalex.org/W7165145351","doi":"https://doi.org/10.1080/03639045.2026.2692054","title":"Development of a transdermal sumatriptan formulation with iontophoresis","display_name":"Development of a transdermal sumatriptan formulation with iontophoresis","publication_year":2026,"publication_date":"2026-06-18","ids":{"openalex":"https://openalex.org/W7165145351","doi":"https://doi.org/10.1080/03639045.2026.2692054","pmid":"https://pubmed.ncbi.nlm.nih.gov/42312369"},"language":"en","primary_location":{"id":"doi:10.1080/03639045.2026.2692054","doi":"https://doi.org/10.1080/03639045.2026.2692054","is_oa":false,"landing_page_url":"https://doi.org/10.1080/03639045.2026.2692054","pdf_url":null,"source":{"id":"https://openalex.org/S162444473","display_name":"Drug Development and Industrial Pharmacy","issn_l":"0363-9045","issn":["0363-9045","1520-5762"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Development and Industrial Pharmacy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5106185377","display_name":"Kenji Mori","orcid":"https://orcid.org/0009-0001-7695-7082","observed_orcids":["https://orcid.org/0009-0001-7695-7082"]},"institutions":[{"id":"https://openalex.org/I61575859","display_name":"Josai International University","ror":"https://ror.org/039pch476","country_code":"JP","type":"education","lineage":["https://openalex.org/I61575859"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kenji Mori","raw_affiliation_strings":["Faculty of Pharmaceutical Sciences, Josai International University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmaceutical Sciences, Josai International University","institution_ids":["https://openalex.org/I61575859"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051023949","display_name":"Takeshi Oshizaka","orcid":"https://orcid.org/0009-0009-7324-8908","observed_orcids":["https://orcid.org/0009-0009-7324-8908"]},"institutions":[{"id":"https://openalex.org/I61575859","display_name":"Josai International University","ror":"https://ror.org/039pch476","country_code":"JP","type":"education","lineage":["https://openalex.org/I61575859"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Takeshi Oshizaka","raw_affiliation_strings":["Faculty of Pharmaceutical Sciences, Josai International University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmaceutical Sciences, Josai International University","institution_ids":["https://openalex.org/I61575859"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086954727","display_name":"Kenji Sugibayashi","orcid":"https://orcid.org/0000-0003-1332-2001","observed_orcids":["https://orcid.org/0000-0003-1332-2001"]},"institutions":[{"id":"https://openalex.org/I201389808","display_name":"Josai University","ror":"https://ror.org/021r6aq66","country_code":"JP","type":"education","lineage":["https://openalex.org/I201389808"]},{"id":"https://openalex.org/I61575859","display_name":"Josai International University","ror":"https://ror.org/039pch476","country_code":"JP","type":"education","lineage":["https://openalex.org/I61575859"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Kenji Sugibayashi","raw_affiliation_strings":["Faculty of Pharmaceutical Sciences, Josai International University","Faculty of Pharmacy and Pharmaceutical Sciences, Josai University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmaceutical Sciences, Josai International University","institution_ids":["https://openalex.org/I61575859"]},{"raw_affiliation_string":"Faculty of Pharmacy and Pharmaceutical Sciences, Josai University","institution_ids":["https://openalex.org/I201389808"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5051023949","https://openalex.org/A5086954727"],"corresponding_institution_ids":["https://openalex.org/I201389808","https://openalex.org/I61575859"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.43111805,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"52","issue":"8","first_page":"1612","last_page":"1622"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sumatriptan","display_name":"sumatriptan","score":0.9990000128746033},{"id":"https://openalex.org/keywords/transdermal-iontophoresis","display_name":"transdermal iontophoresis","score":0.871999979019165},{"id":"https://openalex.org/keywords/transdermal-drug-delivery","display_name":"transdermal drug delivery","score":0.8450000286102295},{"id":"https://openalex.org/keywords/plasma-concentration","display_name":"plasma concentration","score":0.7210000157356262},{"id":"https://openalex.org/keywords/migraine-treatment","display_name":"migraine treatment","score":0.6539999842643738},{"id":"https://openalex.org/keywords/formulation-development","display_name":"formulation development","score":0.48500001430511475},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6359999775886536}],"concepts":[{"id":"https://openalex.org/C183529106","wikidata":"https://www.wikidata.org/wiki/Q1528394","display_name":"Iontophoresis","level":2,"score":0.9617000222206116},{"id":"https://openalex.org/C205679159","wikidata":"https://www.wikidata.org/wiki/Q3375179","display_name":"Transdermal","level":2,"score":0.9372000098228455},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.738099992275238},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6789000034332275},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5899999737739563},{"id":"https://openalex.org/C2778871607","wikidata":"https://www.wikidata.org/wiki/Q416978","display_name":"Sumatriptan","level":4,"score":0.5425999760627747},{"id":"https://openalex.org/C3020079912","wikidata":"https://www.wikidata.org/wiki/Q3918988","display_name":"Plasma concentration","level":2,"score":0.5141000151634216},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.4641999900341034},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4528999924659729},{"id":"https://openalex.org/C2775842315","wikidata":"https://www.wikidata.org/wiki/Q1145270","display_name":"Transdermal patch","level":3,"score":0.3935000002384186},{"id":"https://openalex.org/C2776093070","wikidata":"https://www.wikidata.org/wiki/Q621636","display_name":"Route of administration","level":2,"score":0.3831000030040741},{"id":"https://openalex.org/C3017575891","wikidata":"https://www.wikidata.org/wiki/Q3918988","display_name":"Plasma levels","level":2,"score":0.33500000834465027},{"id":"https://openalex.org/C77281830","wikidata":"https://www.wikidata.org/wiki/Q718608","display_name":"Dosage form","level":2,"score":0.3172000050544739},{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.29989999532699585},{"id":"https://openalex.org/C3020134792","wikidata":"https://www.wikidata.org/wiki/Q79749","display_name":"Human plasma","level":2,"score":0.2996000051498413},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.29030001163482666},{"id":"https://openalex.org/C201253974","wikidata":"https://www.wikidata.org/wiki/Q1330121","display_name":"First pass effect","level":3,"score":0.2888999879360199},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.26919999718666077},{"id":"https://openalex.org/C45904493","wikidata":"https://www.wikidata.org/wiki/Q912807","display_name":"Active ingredient","level":2,"score":0.25940001010894775}],"mesh":[{"descriptor_ui":"D000279","descriptor_name":"Administration, Cutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005782","descriptor_name":"Gels","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007478","descriptor_name":"Iontophoresis","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012867","descriptor_name":"Skin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012869","descriptor_name":"Skin Absorption","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018170","descriptor_name":"Sumatriptan","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018170","descriptor_name":"Sumatriptan","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/03639045.2026.2692054","doi":"https://doi.org/10.1080/03639045.2026.2692054","is_oa":false,"landing_page_url":"https://doi.org/10.1080/03639045.2026.2692054","pdf_url":null,"source":{"id":"https://openalex.org/S162444473","display_name":"Drug Development and Industrial Pharmacy","issn_l":"0363-9045","issn":["0363-9045","1520-5762"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Development and Industrial Pharmacy","raw_type":"journal-article"},{"id":"pmid:42312369","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42312369","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug development and industrial pharmacy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8366432785987854,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W1526280414","https://openalex.org/W1925261632","https://openalex.org/W1970528604","https://openalex.org/W1985663093","https://openalex.org/W2002671537","https://openalex.org/W2005128914","https://openalex.org/W2019755645","https://openalex.org/W2029681329","https://openalex.org/W2037913672","https://openalex.org/W2054205282","https://openalex.org/W2062780301","https://openalex.org/W2073074795","https://openalex.org/W2074627216","https://openalex.org/W2075195402","https://openalex.org/W2075229122","https://openalex.org/W2083120125","https://openalex.org/W2105598729","https://openalex.org/W2117571921","https://openalex.org/W2122771524","https://openalex.org/W2136590567","https://openalex.org/W2136876934","https://openalex.org/W2157286284","https://openalex.org/W2160760798","https://openalex.org/W2168154823","https://openalex.org/W2243357119","https://openalex.org/W2895868360","https://openalex.org/W2898445918","https://openalex.org/W2944078180","https://openalex.org/W3037714890","https://openalex.org/W3043755690","https://openalex.org/W3176413724","https://openalex.org/W3208701883","https://openalex.org/W3217281147","https://openalex.org/W4281969452","https://openalex.org/W4281981946","https://openalex.org/W4309680707","https://openalex.org/W4317870994","https://openalex.org/W4361007059","https://openalex.org/W4388237910","https://openalex.org/W4388975039","https://openalex.org/W4391786267","https://openalex.org/W4402747305","https://openalex.org/W4407607768","https://openalex.org/W4409648533","https://openalex.org/W4413766853"],"related_works":[],"abstract_inverted_index":{"Objective":[0],"A":[1],"transdermal":[2,61,232],"iontophoretic":[3],"formulation":[4,195],"for":[5,15,70,127,142,149,208,234],"sumatriptan":[6,111],"was":[7,24,93,119,171],"approved":[8],"by":[9,83,146],"the":[10,79,114,154,165,200,224],"U.S.":[11],"FDA":[12],"in":[13,26,91,161,169],"2013":[14],"patients":[16,71,235],"who":[17,72],"cannot":[18,73],"take":[19,238],"oral":[20,75,159,239],"medications.":[21,240],"However,":[22],"it":[23,207],"withdrawn":[25],"2020":[27],"due":[28],"to":[29,42,237],"skin":[30],"burns":[31],"and":[32,99,117,178,189,205],"scarring":[33],"associated":[34],"with":[35],"prolonged":[36],"electrical":[37,85],"applications.":[38],"This":[39],"study":[40],"aimed":[41],"determine":[43],"whether":[44],"short-duration,":[45],"low-current":[46,212],"iontophoresis":[47,118,213],"can":[48],"still":[49],"achieve":[50],"therapeutically":[51],"effective":[52],"plasma":[53,89,156,167,217],"concentrations":[54,131],"of":[55,219,226],"sumatriptan.Significance:":[56],"Developing":[57],"a":[58,230],"safe,":[59],"rapid-acting":[60],"delivery":[62],"system":[63],"would":[64],"provide":[65],"an":[66],"alternative":[67,233],"treatment":[68],"option":[69],"tolerate":[74],"medications,":[76],"while":[77],"reducing":[78],"risk":[80],"injury":[81],"caused":[82],"long-term":[84],"exposure.Methods":[86],"The":[87,176,193],"target":[88,166,186,201],"concentration":[90,157,168,218],"rats":[92,170],"calculated":[94,172],"from":[95],"rat":[96],"elimination":[97],"pharmacokinetics":[98],"previously":[100],"reported":[101],"human":[102],"therapeutic":[103,216],"concentrations.":[104],"Rats":[105],"received":[106],"0.04,":[107],"0.2,":[108],"or":[109,124],"0.4%":[110,179],"gel":[112],"on":[113,153],"abdominal":[115],"skin,":[116],"applied":[120,139],"at":[121,181,196],"0.05,":[122],"0.1,":[123],"0.2":[125,140,177,197],"mA/cm2":[126,141,148,183,198],"2":[128],"h.":[129],"Plasma":[130],"were":[132],"measured":[133],"over":[134],"time.":[135],"An":[136],"additional":[137],"experiment":[138],"0.5":[143,150,203],"h":[144,204],"followed":[145],"0.1":[147,182],"h.Results":[151],"Based":[152],"maximal":[155],"after":[158],"administration":[160],"humans":[162],"(16.5":[163],"ng/mL),":[164],"as":[173,229],"0.94":[174],"\u03bcg/mL.":[175],"formulations":[180],"exceeded":[184],"this":[185,227],"within":[187,202],"1.5":[188],"1.0":[190],"h,":[191],"respectively.":[192],"0.2%":[194],"surpassed":[199],"maintained":[206],"3":[209],"h.Conclusions":[210],"Short-duration,":[211],"effectively":[214],"achieved":[215],"sumatriptan.":[220],"These":[221],"findings":[222],"support":[223],"potential":[225],"approach":[228],"safer":[231],"unable":[236]},"counts_by_year":[],"updated_date":"2026-09-21T07:43:02.447757","created_date":"2026-06-19T00:00:00"}